Efficacy as an Important Facet of "Safety" in Clinical Trials: How Can We Do Our Best for Our Patients?

被引:4
|
作者
Talbot, George H. [1 ]
机构
[1] Talbot Advisors LLC, St Davids, PA 19087 USA
关键词
D O I
10.1086/591401
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Ensuring optimal efficacy is an important facet of patient safety during the conduct of a clinical trial, if, by "safety," we mean the anticipation, prevention, and assessment of any event that can have an unfavorable impact on the enrolled patients. This article addresses what could be termed the "nonsafety" aspects of safety during clinical trials, with a focus on situations in which we, as drug developers and clinical investigators, can err and thereby put our study patients at an unanticipated and unintended risk for a poor outcome. Approaches to mitigating the safety risk of efficacy are also discussed.
引用
收藏
页码:S180 / S185
页数:6
相关论文
共 50 条